NCT06970145View on ClinicalTrials.gov

Safety and Efficacy of Amlotinib in the Treatment of Recurrent Craniopharyngioma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

April 25, 2025

Primary Completion Date

April 20, 2027

Study Completion Date

April 20, 2028

Conditions
Craniopharyngiomas
Interventions
DRUG

Anlotinib

Anlotinib Hydrochloride Capsules (12mg),Chiatai Tianqing Pharma (China).

Trial Locations (1)

510515

RECRUITING

Southern Medical University, Nanfang Hospital, Department of Neurosurgery, Guangzhou

All Listed Sponsors
lead

Nanfang Hospital, Southern Medical University

OTHER